- Research Demonstrates GDNF's Ability to Prevent and
Reverse Obesity by Enhancing Fat Metabolism and Energy
Expenditure
- Hoth is developing this therapeutic in
Partnership with the Department of Veterans Affairs
Key Findings from the Study:
- Protection Against High-Fat Diet-Induced Obesity –
GDNF-tg mice exhibited significantly lower body weight and reduced
fat deposition despite consuming a high-fat diet.
- Enhanced Fat Burning and Energy Expenditure – GDNF
increased basal metabolic rate, oxygen consumption, and carbon
dioxide production, leading to higher energy expenditure without
changes in food intake.
- Inhibition of Fat Cell Formation (Adipogenesis) –
GDNF suppressed key genes involved in fat storage, including
PPAR-γ, FASN, and SREBF1, while promoting fat oxidation
pathways.
- Improved Insulin Sensitivity and Glucose
Regulation – GDNF-tg mice showed enhanced glucose
tolerance and lower serum leptin levels, markers of improved
metabolic health.
- Reduced Fatty Liver Disease – GDNF prevented
hepatic steatosis (fat accumulation in the liver), a common
obesity-related complication.
NEW
YORK, March 4, 2025 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage
biopharmaceutical company, today announced preclinical findings
that highlight the potential of Glial Cell Line-Derived
Neurotrophic Factor (GDNF) as a revolutionary treatment
for obesity. The study, conducted in GDNF-transgenic (GDNF-tg)
models, demonstrated that GDNF significantly reduces fat
accumulation, enhances metabolism, and improves insulin
sensitivity, even under high-fat diet conditions.
"These compelling findings reinforce GDNF's potential to
fundamentally alter the way we approach obesity treatment," said
Robb Knie CEO of Hoth Therapeutics. "Unlike traditional weight-loss
interventions that primarily focus on appetite suppression or
caloric restriction, GDNF directly enhances the body's natural
ability to burn fat and increase metabolic efficiency."
Key Findings from the Study:
- Protection Against High-Fat Diet-Induced Obesity – GDNF-tg
mice exhibited significantly lower body weight and reduced fat
deposition despite consuming a high-fat diet.
- Enhanced Fat Burning and Energy Expenditure – GDNF
increased basal metabolic rate, oxygen consumption, and carbon
dioxide production, leading to higher energy expenditure without
changes in food intake.
- Inhibition of Fat Cell Formation (Adipogenesis) – GDNF
suppressed key genes involved in fat storage, including PPAR-γ,
FASN, and SREBF1, while promoting fat oxidation pathways.
- Improved Insulin Sensitivity and Glucose Regulation –
GDNF-tg mice showed enhanced glucose tolerance and lower serum
leptin levels, markers of improved metabolic health.
- Reduced Fatty Liver Disease – GDNF prevented hepatic
steatosis (fat accumulation in the liver), a common obesity-related
complication.
A Paradigm Shift in Obesity Treatment
Obesity is a major global health crisis, affecting over 650
million adults worldwide and contributing to life-threatening
conditions such as type 2 diabetes, cardiovascular disease, and
metabolic syndrome. Current pharmacological treatments often have
limited efficacy or undesirable side effects. Hoth Therapeutics'
research into GDNF suggests a novel mechanism for weight management
that works by enhancing energy metabolism rather than
restricting food intake.
"The data suggest that GDNF-based therapies could offer an
entirely new approach to obesity treatment—one that activates the
body's natural metabolic processes to burn excess fat efficiently,"
added Robb Knie, CEO Hoth
Therapeutics. "This represents a significant advancement over
current anti-obesity drugs, which often fail to maintain long-term
weight loss."
Next Steps in Development
Hoth Therapeutics is actively exploring multiple pathways for
the clinical translation of GDNF-based therapies, including
recombinant protein delivery, gene therapy, and small-molecule
mimetics that can activate the same metabolic pathways. The company
plans to initiate further preclinical and clinical development
efforts to bring this potential therapy closer to patients in
need.
For more information on Hoth Therapeutics and its innovative
pipeline, please visit www.hoththerapeutics.com
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment options.
To learn more, please
visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release
includes forward-looking statements based upon Hoth's
current expectations, which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product
candidates and any other product
candidates we may develop, and the labeling
under any approval we may
obtain; the timing and costs of clinical trials,
and the timing
and costs of other expenses; market acceptance
of our products; the ultimate impact
of the current coronavirus pandemic,
or any other health epidemic, on our business,
our clinical trials, our research programs, healthcare systems, or
the global economy as a whole; our intellectual property; our
reliance on third-party organizations; our competitive position;
our industry environment; our anticipated financial and operating
results, including anticipated sources of revenues; our assumptions
regarding the size of the available market, benefits of our
products, product pricing, and timing of product launches;
management's expectation with respect to future acquisitions;
statements regarding our goals, intentions, plans, and
expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors"
in Hoth's most recent Annual Report on Form 10-K and Hoth's
other filings made with the U. S. Securities and Exchange
Commission. All such statements speak only as of the date made.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates, and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance,
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-findings-on-gdnfs-potential-as-a-game-changer-in-obesity-treatment-and-reduced-fatty-liver-disease-302391087.html
SOURCE Hoth Therapeutics, Inc.
